Abstract
Neovascularization is intimately involved in tumor survival, progression, and spread, factors known to contribute significantly to treatment failures. Thus, strategies targeting the tumor blood vessel support network may offer not only unique therapeutic opportunities in their own right, but also novel means of enhancing the efficacies of conventional anticancer treatments. This article reviews one such therapeutic approach directed at the tumor blood vessel support network. Vascular disrupting therapies seek the destruction of the established neovasculature of actively growing tumors. The goal of these therapies is to cause a rapid and catastrophic shutdown in the vascular function of the tumor in order to arrest the blood flow and produce tumor cell death as a result of oxygen and nutrient deprivation and the build up of waste products.
Similar content being viewed by others
References
Arap W, Pasqualini R, Ruoslahti E (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279:377–380
Ausprunk D, Folkman J (1977) Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 14:53–65
Baguley BC, Ching LM (2002) DMXAA: an antivascular agent with multiple host responses. Int J Radiat Oncol Biol Phys 54:1503–1511
Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, Ryan AJ (2002) Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8:1974–1983
Bloemendal HJ, Logtenberg T, Voest EE (1999) New strategies in anti-vascular cancer therapy. Eur J Clin Invest 29:802–809
Chaplin DJ, Dougherty GJ (1999) Tumour vasculature as a target for cancer therapy. Br J Cancer 80:57–64
Chaplin DJ, Horsman MR, Siemann DW (2006) Current development status of small-molecule vascular disrupting agents. Curr Opin Invest Drugs 7:522–528
Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ, Hill SA (2002) ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 62:7247–7253
Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR, Remick SC (2002) A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62:3408–3416
Ellis LM, Takahashi Y, Liu W, Shaheen RM (2000) Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist 5 (Suppl 1):11–15
Ellis LM, Liu W, Ahmad SA, Fan F, Jung YD, Shaheen RM, Reinmuth N (2001) Overview of angiogenesis: biologic implications for antiangiogenic therapy. Semin Oncol 28:94–104
Folkman J (1986) How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Res 46:467–473
Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29:15–18
Galbraith SM, Chaplin DJ, Lee F, Stratford MR, Locke RJ, Vojnovic B, Tozer GM (2001a) Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res 21:93–102
Galbraith SM, Lodge MA, Taylor NJ, Maxwell R, Tozer GM, Prise V, Wilson I, Sena L, Robbins A, Padhani A, Padhani G (2001b) Combretastatin A4 phosphate (CA4P) reduces tumor blood flow in animals and man, demonstrated by MRI. Proc Am Soc Clin Oncol 20:278
Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC (1999) In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 81:1318–1327
Hendrix MJ, Seftor EA, Hess AR, Seftor RE (2003) Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 3:411–421
Horsman MR, Murata R, Overgaard J (2002) Combination studies with combretastatin and radiation: effects in early and late responding normal tissues. Radiother Oncol 64:S50
Horsman MR, Siemann DW (2006) Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 66:11520–11539
Kerbel RS (2000) Tumor angiogenesis: past, present and the near future. Carcinogenesis 21:505–515
Kestell P, Zhao L, Jameson MB, Stratford MR, Folkes LK, Baguley BC (2001) Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents. Clin Chim Acta 314:159–166
Konerding MA, Miodonski AJ, Lametschwandtner A (1995) Microvascular corrosion casting in the study of tumor vascularity: a review. Scanning Microsc 9:1233–1244
Konerding MA, Ackern C van, Fait E, Steinberg F, Streffer C (2002) Morphological aspects of tumor angiogenesis and microcirculation. In: Molls M, Vaupel P (eds) Blood perfusion and microenvironment of human tumors. Springer, Berlin Heidelberg New York, pp 5–17
Landuyt W, Ahmed B, Nuyts S, Theys J, Op de Beeck M, Rijnders A, Anné J, Oosterom A van, Bogaert W van den, Lambin P (2001) In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int J Radiat Oncol Biol Phys 49:443–450
Li L, Rojiani AM, Siemann DW (2002) Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi’s sarcoma. Acta Oncol 41:91–97
McKeage MJ, Fong P, Jeffery M, Baguley BC, Kestell P, Ravic M, Jameson MB (2006) 5,6- Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. Clin Cancer Res 12:1776–1784
Murata R, Siemann DW, Overgaard J, Horsman MR (2001a) Improved tumor response by combining radiation and the vascular damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiat Res 156:503–509
Murata R, Siemann DW, Overgaard J, Horsman MR (2001b) Interaction between combretastatin A4 disodium phosphate and radiation in murine tumours. Radiother Oncol 60:155–161
Ruoslahti E (2002) Specialization of tumour vasculature. Nat Rev Cancer 2:83–90
Salmon HW, Siemann DW (2006) Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity. Clin Cancer Res 12:4090–4094
Shaked Y, Bertolini F, Emmenegger U, Lee CR, Kerbel RS (2006) On the origin and nature of elevated levels of circulating endothelial cells after treatment with a vascular disrupting agent. J Clin Oncol 24:4040–4041
Siemann DW (2002) Vascular targeting agents. Horiz Cancer Ther 3:4–15
Siemann DW (2004) Therapeutic strategies that selectively target and disrupt established tumor vasculature. Hematol Oncol Clin North Am 18:1023–1037
Siemann DW, Chaplin DJ (2007) An update on the clinical development of drugs to disable tumor vasculature. Expert Opin Drug Discov 2:1357–1367
Siemann DW, Horsman MR (2008) Small molecule vascular disrupting agents in cancer therapy. In: Ellis LM, Teicher B (eds) Antiangiogenesis agents. Humana, Towaha, pp 297–310
Siemann DW, Rojiani AM (2002) Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 53:164–171
Siemann DW, Shi W (2003) Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy. Semin Radiat Oncol 13:53–61
Siemann DW, Shi W (2004) Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int J Radiat Oncol Biol Phys 60:1233–1240
Siemann DW, Mercer E, Lepler SE, Rojiani AM (2002) Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 99:1–6
Siemann DW, Chaplin DJ, Horsman MR (2004) Vascular-targeting therapies for treatment of malignant disease. Cancer 100:2491–2499
Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR, Marme D, LoRusso PM (2005) Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 11:416–420
Streubel B, Chott A, Huber D, Exner M, Jager U, Wagner O, Schwarzinger I (2004) Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 351:250–259
Tannock IF (1970) Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor. Cancer Res 30:2470–2477
Thorpe PE (2004) Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10:415–427
Tozer GM, Kanthou C, Baguley BC (2005) Disrupting tumour blood vessels. Nat Rev Cancer 5:423–435
Vincent L, Kermani P, Young LM, Cheng J, Zhang F, Shido K, Lam G, Bompais-Vincent H, Zhu Z, Hicklin DJ, Bohlen P, Chaplin DJ, May C, Rafii S (2005) Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 115:2992–3006
Wilson WR, Li AE, Cowan DS, Siim BG (1998) Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Int J Radiat Oncol Biol Phys 42:905–908
Author information
Authors and Affiliations
Corresponding author
Additional information
The authors’ work is supported by the National Cancer Institute (Public Health Service grants CA084408 and CA089655) and the Danish Cancer Society.
Rights and permissions
About this article
Cite this article
Siemann, D.W., Horsman, M.R. Vascular targeted therapies in oncology. Cell Tissue Res 335, 241–248 (2009). https://doi.org/10.1007/s00441-008-0646-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00441-008-0646-0